SGMT Sagimet Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SGMT

Price (delayed)

$7.11

Market cap

$435.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.35

Enterprise value

$398.43M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 75
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 13

We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, ...

Highlights
The debt has plunged by 50% from the previous quarter
The net income is up by 24% year-on-year and by 15% since the previous quarter
The equity has declined by 26% year-on-year and by 8% since the previous quarter
The quick ratio has declined by 11% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://sagimet.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of SGMT

SGMT stock price

How has the Sagimet Biosciences stock price performed over time
Intraday
3.64%
1 week
-2.2%
1 month
-10%
1 year
74.26%
YTD
20.1%
QTD
36.08%

Financial performance

How have Sagimet Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$48.74M
Net income
-$43.51M
Gross margin
N/A
Net margin
N/A
SGMT's operating income is up by 26% YoY and by 14% QoQ
The net income is up by 24% year-on-year and by 15% since the previous quarter

Price vs fundamentals

How does SGMT's price correlate with its fundamentals

Growth

What is Sagimet Biosciences's growth rate over time

Valuation

What is Sagimet Biosciences stock price valuation
P/E
N/A
P/B
2.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 23% YoY and by 15% from the previous quarter
The equity has declined by 26% year-on-year and by 8% since the previous quarter
SGMT's price to book (P/B) is 21% higher than its last 4 quarters average of 1.8

Efficiency

How efficient is Sagimet Biosciences business performance
The return on invested capital rose by 19% year-on-year and by 12% since the previous quarter
Sagimet Biosciences's return on assets has increased by 8% QoQ but it has decreased by 4.1% YoY
The company's return on equity rose by 8% QoQ but it fell by 7% YoY

Dividends

What is SGMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SGMT.

Financial health

How did Sagimet Biosciences financials performed over time
Sagimet Biosciences's total liabilities has decreased by 26% YoY but it has increased by 3.8% QoQ
Sagimet Biosciences's total assets has decreased by 26% YoY and by 7% from the previous quarter
The debt is 100% less than the equity
The debt has plunged by 50% from the previous quarter
The equity has declined by 26% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.